Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina
- 12 April 2011
- journal article
- clinical trial
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 45 (3) , 161-168
Abstract
We evaluated the feasibility, safety and efficacy of intra-myocardial injection of autologous mesenchymal stromal cells derived endothelial progenitor cell (MSC) in patients with stable coronary artery disease (CAD) and refractory angina in this first in man trial. A total of 31 patients with stable CAD, moderate to severe angina and no further revascularization options, were included. Bone marrow MSC were isolated and culture expanded for 6-8 weeks. It was feasible and safe to establish in-hospital culture expansion of autologous MSC and perform intra-myocardial injection of MSC. After six months follow-up myocardial perfusion was unaltered, but the patients increased exercise capacity (p < 0.001), reduction in CCS Class (p < 0.001), angina attacks (p < 0.001) and nitroglycerin consumption (p < 0.001), and improved Seattle Angina Questionnaire (SAQ) evaluations (p < 0.001). For all parameters there was a tendency towards improved outcome with increasing numbers of cells injected. In the MRI substudy: ejection fraction (p < 0.001), systolic wall thickness (p = 0.03) and wall thickening (p = 0.03) all improved. The study demonstrated that it was safe to treat patients with stable CAD with autologous culture expanded MSC. Moreover, MSC treated patients had significant improvement in left ventricular function and exercise capacity, in addition to an improvement in clinical symptoms and SAQ evaluations.Keywords
This publication has 24 references indexed in Scilit:
- Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome?EPMA Journal, 2011
- Cells as biologics for cardiac repair in ischaemic heart failureHeart, 2010
- Mesenchymal Stromal Cells for Cardiovascular Repair: Current Status and Future ChallengesFuture Cardiology, 2009
- Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) TrialEuropean Heart Journal, 2009
- Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized studyNature Clinical Practice Cardiovascular Medicine, 2008
- Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial InfarctionNew England Journal of Medicine, 2006
- Intracoronary Injection of Mononuclear Bone Marrow Cells in Acute Myocardial InfarctionNew England Journal of Medicine, 2006
- Myocardial Gene Expression of Angiogenic Factors in Human Chronic Ischemic Myocardium: Influence of Acute Ischemia/Cardioplegia and ReperfusionMicrocirculation, 2006
- Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trialThe Lancet, 2006
- Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trialThe Lancet, 2004